Top Ten most popular articles on this week

pharmafile | October 4, 2019 | News story | Medical Communications  

Another week comes to an end at Pharmafile and we run down with the top 10 articles for the week. The past seven days saw numerous studies, findings and research come out of the European Society for Medical Oncology (ESMO) and additionally saw rejections and approvals across the board. Here they are:

10. AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new data on Tagrisso (osimertinib) in the first-line treatment of locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

9. Roche secures US paediatric approval for Rituxan in two rare forms of vasculitis

Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination with glucocorticoids for the treatment of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MA) in children over the age of two years old.

8. GSK’s Zejula slows disease progression in a range of ovarian cancers

At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for the maintenance of first-line ovarian cancer that has responded to platinum-based chemotherapy.

7. AstraZeneca strikes global commercial rights deal for $243m

Cambridge-headquartered AstraZeneca have agreed to sell certain global commercial rights for its Losec brand, in a deal that is worth around $243 million.

6. Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer

Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical Oncology (ESMO) congress, showing promising performance in combination with platinum-based chemotherapy in the first-line treatment of previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy.

5. ESMO studies show CD4K/6 inhibitor and fulvestrant improves OS in breast cancer

Detailed findings from two Phase III trials presented at the European Society for Medical Oncology showed that treatment with a CDK4/6 inhibitor plus fulvestrant improved overall survival in women with advanced breast cancer versus fulvestrant and placebo.

4. FDA grants Johnson & Johnson’s Invokana new kidney disease approval

Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating diabetic kidney disease (DKD) and to reduce the risk of hospitalisation for heart failure in patients with type 2 diabetes and DKD.

3. NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and Wales for the treatment of unresectable, metastatic triple A breast cancer.

2. MSD’s Keytruda meets primary endpoint in triple-negative breast cancer

MSD have announced results from its Phase 3, KEYNOTE-522 trial that pathological complete response (pCR) in patients with early triple-negative breast cancer significantly increased from 51.2% in the placebo group to 64.8% for those given Keytruda in combination with chemotherapy.

1. AZ and MSD’s parp inhibitor Lynparza cuts risk of progression and death in prostate cancer

AstraZeneca and MSD have shown in their Phase 3 PROfound trial, PARP inhibitor Lynparza (olaparib) reduced the risk of disease progression or death by up to 66% in men with metastic castration-resistant prostate cancer (mCRPC) whose disease had progressed on prior new hormonal agent treatments.

Related Content

No items found

Latest content